Drug intelligence / Profile preview

RSC-1255

Development stage: Phase 1
Lead developer: RasCal Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

RSC-1255 is an orally bioavailable, small-molecule direct pan-mutant and wild-type RAS inhibitor developed by RasCal Therapeutics for the treatment of advanced solid tumors. It selectively targets, binds to, and inhibits both wild-type and mutated forms of Ras protein, thereby inhibiting Ras-dependent signaling pathways that drive tumor cell proliferation in cancers where Ras is overexpressed or mutated. Additionally, it acts as a V-ATPase inhibitor with nanomolar potency against a spectrum of Ras-mutant cancer cells. The drug is currently being evaluated in Phase 1 clinical trials for various advanced solid malignancies including colorectal cancer, lung cancer, pancreatic cancer, and glioblastoma[1][3][4][5][8].

Other names: Ras inhibitor RSC-1255

Targets

HRAS (H-Ras protein)

Beyond the preview

Go deeper on RSC-1255.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSC-1255.

Explore the full profile